An independent overview of the eConsent market for clinical trial professionals evaluating electronic informed consent platforms.
Electronic informed consent software replaces traditional paper-based patient consent forms in clinical research with a validated digital process.
Rather than handing a participant a stack of printed documents to sign, eConsent platforms deliver interactive, multimedia-rich consent information on a tablet, smartphone, or computer (at a clinical site, at home, or anywhere with an internet connection).
A compliant eConsent solution must meet FDA 21 CFR Part 11, EU Annex 11, ICH E6(R2) GCP, and GDPR. It must support remote and in-person consent workflows, provide full audit trails, enable re-consent when protocols are amended, and make consent records accessible to trial monitors and regulators.
The regulatory landscape for remote eConsent has evolved significantly since the COVID-19 pandemic accelerated adoption. FDA guidance and EMA guidance both permit remote eConsent under appropriate conditions. The result is a market that has grown rapidly as sponsors standardise on eConsent for decentralised clinical trials.
The eConsent market is estimated at over USD 1.3 billion in 2025 and growing at 14-16% CAGR. Key dynamics are shaping how sponsors and sites choose platforms.
Standalone eConsent vendors face pressure from integrated clinical platforms that bundle eConsent with EDC, eCOA, and RTSM. Sponsors managing multiple systems often prefer to consolidate on a single vendor where eConsent is natively integrated with the trial database.
eConsent platforms increasingly compete on the quality of the participant experience, including video content, comprehension quizzes, multilingual support, and accessibility for participants with low health literacy or disabilities.
Despite broad acceptance, some regulatory markets (notably Japan and certain emerging markets) still impose restrictions on fully remote consent, requiring a witnessed or hybrid process. Platform selection should account for the geographic scope of the trial.
PMCF studies under EU MDR involve long-duration follow-up with diverse patient populations, often at multiple sites across Europe. These studies benefit from eConsent platforms that handle longitudinal re-consent workflows and are compatible with both interventional and observational data collection.
When assessing platforms, prioritise the capabilities that match your trial design and participant population.
Video-enhanced consent delivery
The following profiles cover the principal eConsent vendors in the market. Capabilities reflect publicly documented information as of early 2026.
Cloud-native unified clinical platform with integrated eConsent, EDC, eCOA, and RTSM
Native integration with Castor EDC means consent data is captured and linked directly to the trial database without manual reconciliation. Supports remote, in-person, and hybrid consent. Re-consent workflows for protocol amendments. Multilingual and accessibility-compliant. Specific support for medical device and PMCF studies under EU MDR. Transparent per-study pricing.
Newer market entrant for eConsent compared to standalone specialists. Multimedia content creation tools are available but less feature-rich than some dedicated eConsent platforms.
Part of the Veeva Vault Clinical Suite, tightly integrated with Veeva CTMS and Vault EDC
Excellent integration for Veeva-native organisations. Enterprise-grade participant portal, site management tools, and regulatory document management. Strong multilingual support. Secure, cloud-based delivery with validated environment.
Value is primarily realised in a fully Veeva environment. Enterprise pricing with multi-year contracts. Standalone deployment has limited differentiation from other enterprise options.
Part of the Medidata Patient Cloud, bundled with Rave EDC and Medidata’s broader patient engagement platform
Deep integration with Medidata Rave for large pharma Rave-centric operations. Comprehensive participant engagement tools including reminders, retention features, and wearables integration. Extensive global deployment history.
Primarily valuable for existing Medidata customers. Complex and consultant-dependent implementation. Enterprise pricing model. Less competitive outside the Medidata ecosystem.
Dedicated eConsent and clinical communications platform with a focus on participant engagement and comprehension
Purpose-built for eConsent with deep expertise in participant-facing content design. Comprehension quizzes, video-rich consent, and health literacy tools are particularly strong. Global deployment across 90+ countries. Supports BYOD and site-provisioned tablet workflows.
Not natively integrated with most EDC platforms; requires a separate integration project. Enterprise contract model. Customers must manage separate EDC relationships.
US-focused site document management and eConsent platform
Popular among US clinical sites for integrated site binder, regulatory document management, and eConsent workflows. Strong site adoption and site staff usability. Well suited to US-centric study programmes.
Primarily a US market product with limited international footprint. eConsent feature set is less comprehensive than dedicated eConsent specialists. Participant portal capabilities are more limited.
Life sciences-specific configuration of the DocuSign e-signature platform
Extremely broad brand recognition and trust for electronic signatures. 21 CFR Part 11 and EU Annex 11 compliant. Easy integration via API with most EDC and CTMS platforms. Familiar user experience for participants and investigators.
DocuSign Life Sciences is primarily an e-signature and basic consent flow tool, not a full-featured eConsent platform. It lacks the participant portal, multimedia content, comprehension assessments, and clinical workflow features of purpose-built eConsent solutions. Not suitable as a standalone consent solution for complex trials.
Key capabilities across the six eConsent platforms profiled above. Ratings reflect publicly documented capabilities as of early 2026.
| Feature | Castor | Veeva Vault eConsent | Medidata eConsent | Signant Health | Florence | DocuSign Life Sciences |
|---|---|---|---|---|---|---|
| Deployment | Cloud SaaS | Cloud SaaS | Cloud SaaS | Cloud SaaS | Cloud SaaS | Cloud SaaS |
| EDC integration | ✓ (Castor EDC native) | ✓ (Veeva Vault EDC) | ✓ (Medidata Rave) | 3rd-party | 3rd-party | 3rd-party |
| Remote / eConsent at home | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| In-person tablet signing | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Video / telemedicine support | ✓ | ✓ | ✓ | ✓ | Partial | Partial |
| Re-consent workflow | ✓ | ✓ | ✓ | ✓ | ✓ | Partial |
| Participant portal | ✓ | ✓ | ✓ | ✓ | ✓ | ✗ |
| Multi-language support | ✓ | ✓ | ✓ | ✓ | Partial | ✓ |
| Accessible design (WCAG) | ✓ | ✓ | ✓ | Partial | Partial | ✓ |
| 21 CFR Part 11 / Annex 11 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| GDPR / data residency | ✓ (EU) | ✓ | ✓ | ✓ | US primary | ✓ |
| DCT / hybrid trial ready | ✓ | ✓ | ✓ | ✓ | ✓ | Partial |
| Medical device / MDR support | ✓ (PMCF) | Partial | Partial | Partial | ✗ | ✗ |
| Pricing model | Transparent, per-study | Enterprise contract | Enterprise contract | Enterprise contract | Subscription / subscription | Per-document / subscription |
✓ = capability confirmed in public documentation. ✗ = not offered. “Partial” = available with restrictions or via third-party integration.
When assessing platforms, prioritise the capabilities that match your trial design and participant population.
If you are already committed to an EDC platform that offers integrated eConsent (Castor, Veeva, Medidata), strong arguments exist for using the native eConsent module: a single audit trail, reduced integration complexity, unified participant records, and simpler regulatory submission packages. The trade-off is that integrated modules may lack the depth of purpose-built solutions for comprehension-focused or multimedia-heavy consent designs.
Studies designed for fully remote participant enrolment require eConsent platforms with home-use functionality: video support, clear mobile UX, asynchronous completion, and witness or legally authorised representative workflows where required by regulation. Studies running primarily in-site settings have more flexibility but benefit from tablet-based consent to eliminate paper, improve audit trails, and speed up site workflows. Learn more about decentralised clinical trials and the role eConsent plays in them.
Trials involving elderly participants, those with low health literacy, rare disease populations, or paediatric participants with parent/guardian consent requirements impose specific demands on eConsent design. Comprehension quizzes, plain-language summaries, audio narration, and accessible interfaces (WCAG 2.1 AA compliance) are important features to evaluate when the participant population may have difficulties with standard digital consent.
Protocols in long-running studies or those with iterative design (particularly platform trials, registry studies, and PMCF studies) often require multiple re-consent events over the course of a participant’s involvement. Evaluate how each platform handles re-consent notifications, incomplete re-consent tracking, and the impact of unanswered re-consent requests on data continuity.
Most platforms on this page are compliant with US FDA 21 CFR Part 11 and EU Annex 11 requirements. For studies spanning Asia-Pacific, Latin America, or markets with stricter local requirements on remote consent, verify specific country-level compliance documentation with the vendor before selection.
Electronic signature (e-signature) refers specifically to the act of signing a document electronically, replacing a physical ink signature. Electronic informed consent (eConsent) is a complete process: it encompasses the delivery of information to the participant, comprehension assessment, opportunity for questions, the consent signature, and ongoing consent management including re-consent for protocol amendments. An e-signature tool like DocuSign can capture signatures, but it does not constitute a full eConsent solution for complex clinical trials.
Yes, with conditions. Both the FDA (21 CFR Part 50, with updated eConsent guidance) and EMA accept eConsent as a valid method of obtaining informed consent in clinical trials. Requirements include ensuring participants can ask questions, that comprehension is assessed, that consent is freely given, and that full audit trails are maintained. Remote eConsent specifically has additional requirements around verification of participant identity and the availability of a witness in certain contexts. Sponsors should review the most current agency guidance and consult with regulatory affairs before implementing remote-only consent.
Yes. eConsent is a foundational technology for decentralised and hybrid trials. Remote eConsent allows participants to review consent materials and sign at home on a personal device, eliminating the need for a site visit at study entry. All major eConsent platforms, including Castor, support BYOD remote consent with secure participant authentication, video conferencing integration for investigator discussions, and electronic witness workflows.
When a protocol amendment triggers a re-consent requirement, the eConsent platform generates notifications to affected participants (typically via email or SMS) directing them to review the updated consent document. The system tracks which participants have acknowledged the amendment and which have not, allowing site staff and monitors to follow up with non-responders. Castor’s eConsent module maintains a full re-consent audit trail linked to the participant’s trial record in the EDC.
Post-Market Clinical Follow-Up (PMCF) studies under EU MDR 2017/745 often run for years with participants recruited across multiple European countries. Key eConsent requirements for PMCF include: multilingual consent forms; long-term participant identity verification; re-consent management for protocol updates; GDPR-compliant data processing agreements; and support for observational study consent designs (which differ from interventional trial consent). Castor’s eConsent module is specifically designed to support these requirements in the context of its broader MDR/PMCF study capabilities.
Castor eConsent is natively integrated with Castor EDC, providing a single platform for consent management and clinical data capture without any integration project. For organisations using a different EDC system, Castor provides API documentation to enable data exchange. The native integration benefits (unified participant records, shared audit trails, single login, and simplified data locking) are only available when using Castor EDC and eConsent together.